Microglia and inflammatory mechanisms in the clearance of amyloid β peptide

GLIA

Volumn 40, Issue 2, 2002, Pages 260-269

  Rogers, Joseph ^a   Strohmeyer, Ron ^a   Kovelowski, C J ^a   Li, Rena ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Amyloid peptide; Complement; Microglia

Indexed keywords

AMYLOID BETA PROTEIN; ANTIGEN;

ALZHEIMER DISEASE; ANIMAL; ANTIGEN ANTIBODY COMPLEX; CHEMOTAXIS; ENCEPHALITIS; HUMAN; IMMUNOLOGY; METABOLISM; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; PHAGOCYTOSIS; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS; CHEMOTAXIS; ENCEPHALITIS; HUMANS; MICROGLIA; PHAGOCYTOSIS;

EID: 0036849021     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10153     Document Type: Review

References (143)

1. Abbas AK, Lichtman AH, Pober JS. 1994a. Antibodies and antigens. In: Abbas AK, Lichtman AH, Pober JS, editors. Cellular and Molecular Immunology, Philadelphia: WB Saunders. p 33-64.
2. Abbas A, Lichtman AH, Pober JS. 1994b. The complement system. In: Abbas AK, Lichtman AH, Pober JS, editors. Cellular and Molecular Immunology. Philadelphia: WB Saunders. p 295-315.
3. Akiyama H, Schwab C, Kondo H, Mori H, Kametani F, Ikeda K, McGeer PL. 1996. Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. Neurosci Lett 206:169-172.
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
5. Alexander JJ, Hack BK, Cunningham PN, Quigg RJ. 2001. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 276: 32129-32135.
6. Anderson AJ, Cummings BJ, Cotman CW. 1994. Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: Association with pathology. Exp Neurol 125:286-295.
7. 2. Biochim Biophys Acta 1488:149-158.
8. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD. 1996. Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res 43:190-202.
9. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
10. Blasko I, Apochal A, Boeck G, Hartmann T, Grubeck-Loebenstein B, Ransmayr G. 2001. Ibuprofen decreases cytokine-induced amyloid Beta production in neuronal cells. Neurobiol Dis 8:1094-1101.
11. Bockow B, Mannik M. 1981. Clearance and tissue uptake of immune complexes in complement-depleted and control mice. Immunology 42:497-504.
12. Boissiere F, Hunot S, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y, Hirsch EC. 1997. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. NeuroReport 8:2849-2852.
13. Bradt BM, Kolb WP, Cooper NR. 1998a. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188:431-438.
14. Bradt BM, Kolb WP, Cooper NR. 1998b. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188:431-438.
15. Bush AI, Beyreuther K, Masters CL. 1993. The beta A4 amyloid protein precursor in human circulation. Ann N Y Acad Sci 695:175-182.
16. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG. 2000. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975-979.
17. Colten HR, Ooi YM, Edelson PJ. 1979. Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 332:482-490.
18. Cooper NR. 1969. Immune adherence by the fourth component of complement. Science 165:396-398.
19. Cooper NR. 1973. Activation of the complement system. Contemp Top Mol Immunol 2:155-183.
20. Cooper NR, Nemerow GR. 1985. Complement effector mechanisms in health and disease. J Invest Dermatol 85:39s-46s.
21. Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB. 1976. Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway. J Exp Med 144: 970-984.
22. Cribbs DH, Velazquez P, Soreghan B, Glabe CG, Tenner AJ. 1997. Complement activation by cross-linked truncated and chimeric full-length beta-amyloid. NeuroReport. 8:3457-3462.
23. Daly J and Kotwal GJ. 1998. Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging 19:619-627.
24. Davis JB, McMurray HF, Schubert D. 1992. The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun 189:1096-1100.
25. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850-8855.
26. Edberg JC, Tosic L, Taylor RP. 1989. Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice. Clin Immunol Immunopathol 51:118-132.
27. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. 1989. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol 56:259-262.
28. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. 1996. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382:716-719.
29. Emmerling MR, Watson MD, Raby CA, Spiegel K. 2000. The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta 1502:158-171.
30. Ferrer I, Segui J, Planas AM. 1996. Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. Neuropathol Appl Neurobiol 22:521-526.
31. Ferrer I, Marti E, Lopez E, Tortosa A. 1998. NF-κB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol Appl Neurobiol 24:271-277.
32. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE. 1998. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 4:480-489.
33. Fingeroth JD, Benedict MA, Levy DN, Strominger JL. 1989. Identification of murine complement receptor type 2. Proc Natl Acad Sci U S A 86:242-246.
34. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. 1992. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol (Berl) 84:225-233.
35. Frautschy SA, Cole GM, Baird A. 1992. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer betaamyloid. Am J Pathol 140:1389-1399.
36. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. 1998. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307-317.
37. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP. 1998. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis. J Immunol 160:3543-3554.
38. Gehrmann J, Schoen SW, Kreutzberg GW. 1991. Lesion of the rat entorhinal cortex leads to a rapid microglial reaction in the dentate gyrus. A light and electron microscopical study. Acta Neuropathol (Berl) 82:442-455.
39. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD. 1996. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67:880-883.
40. Graeber MB, Streit WJ, Kreutzberg GW. 1988. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 21:18-24.
41. Haas C, Hung AY, citron M, Teplow DB, Selkoe DJ. 1995. beta-Amyloid, protein processing and Alzheimer's disease. Arzneimittelforschung 45:398-402.
42. Haga S, Akai K, Ishii T. 1989. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (Berl) 77:569-575.
43. Haga S, Ikeda K, Sato M, Ishii T. 1993. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 601:88-94.
44. Haga S, Aizawa T, Ishii T, Ikeda K. 1996. Complement gene expression in mouse microglia and astrocytes in culture: Comparisons with mouse peritoneal macrophages. Neurosci Lett 216:191-194.
45. Halma C, Daha MR, Camps JA, Evers-Schouten JH, Pauwels EK, Van E. 1992. Deficiency of complement component C3 is associated with accelerated removal of soluble 123I-labelled aggregates of IgG from the circulation. Clin Exp Immunol 90:394-400.
46. Hebert LA. 1991a. The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 17:352-361.
47. Hebert LA. 1991b. The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 17:352-361.
48. Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, Mucke L. 1999. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am J Pathol 155:1741-1747.
49. Hyman BT, Marzloff K, Arriagada PV. 1993. The lack of accumulation of senile plaques or amyloid burden n Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 52:594-600.
50. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R. 2001. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49:808-810.
51. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
52. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Farquhar C. 1994. Morphogenesis of amyloid plaques in 87V murine scrapie. Neuropathol Appl Neurobiol 20:535-542.
53. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. 1994. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152 :5050-5059.
54. Johnson SA, Lampert-Etchells M, Pasinetti GM, Rozovsky I, Finch CE. 1992. Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 13:641-648.
55. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE. 2002. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41:922-928.
56. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. 1997. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 94:2642-2647.
57. Kaur C, Chan YG, Ling EA. 1992. Ultrastructural and immunocytochemical studies of macrophages in an excitotoxin induced lesion in the rat brain. J Hirnforsch 33:645-652.
58. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. 1997. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 232:418-421.
59. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T. 1997. Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer's disease brains. Neurosci Lett 237:17-20.
60. Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. 1999. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 254:582-586.
61. Kopec KK, Carroll RT. 1998. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J Neurochem 71:2123-2131.
62. Kopec KK, Carroll RT. 2000. Phagocytosis is regulated by nitric oxide in murine microglia. Nitric Oxide 4:103-111.
63. Korotzer AR, Watt J, Cribbs D, Tenner AJ, Burdick D, Glabe C, Cotman CW. 1995. Cultured rat microglia express C1q and receptor for C1q: Implications for amyloid effects on microglia. Exp Neurol 134:214-221.
64. Kovelowski CJ, Lue LF, Walker D, Mueller K, Seetharaman R, Rogers J. 2001. Opsonization and anti-inflammatory drug effects on microglial chemotaxis, phagocytosis, and cytokine secretion in vitro after amyloid peptide exposure. Soc Neurosci Abstr Program No 890.11.
65. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. 1996. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081.
66. Kurtz CB, Paul MS, Aegerter M, Weis JJ, Weis JH. 1989. Murine complement receptor gone family. II. Identification and characterization of the murine homolog (Cr2) to human CR2 and its molecular linkage to Crry. J Immunol 143:2058-2067.
67. Kurtz CB, O'Toole E, Christensen SM, Weis JH. 1990. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 144:3581-3591.
68. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. 1995. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol 61:71-78.
69. Lee RK, Wurtman RJ. 2000. Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann N Y Acad Sci 920:261-268.
70. Li R, Shen Y, Yang LB, Lue LF, Finch C, Rogers J. 2000. Estrogen enhances uptake of amylold beta-protein by microglia derived from the human cortex. J Neurochem 75:1447-1454.
71. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
72. Lorton D, Schaller J, Lala A, De Nardin E. 2000. Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's Disease. Neurobiol Aging 21:463-473.
73. Lu W, Mi R, Tang H, Liu S, Fan M, Wang L. 1998. Over-expression of c-fos mRNA in the hippocampal neurons in Alzheimer's disease. Chin Med J (Engl) 111:35-37.
74. Luber-Narod J, Rogers J. 1988. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett 94:17-22.
75. Lue LF, Brachova L, Rogers J. 1997. Modeling Aβ deposition in cultures of Alzheimer's glia and hnt neurons. Neurosci Abs 23:533.
76. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. 2001. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35:72-79.
77. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. 2001a. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. Exp Neurol 171: 29-45.
78. Lue LF, Walker DG, Rogers J. 2001b. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22:945-956.
79. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. 2001c. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35:72-79.
80. Lukiw WJ, Bazan NG. 1998. Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 53:583-592.
81. MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RL, Synek B, Mee E, Connor B, Dragunow M. 1997. Expression of Fos, Jun, Krox family proteins in Alzheimer's disease. Exp Neurol 147:316-332.
82. Maeda K, Nakai M, Maeda S, Kawamata T, Yamaguchi T, Tanaka C. 1997. Possible different mechanism between amyloid-beta (25-35)-and substance P-induced chemotaxis of murine microglia. Gerontology 43(suppl)1:11-15.
83. Marcus DL, Strafaci JA, Miller DC, Masia S, Thomas CG, Rosman J, Hussain S, Freedman ML. 1998. Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging 19:393-400.
84. McGeer PL, Akiyama H, Itagaki S, McGeer EG. 1989a. Immune system response in Alzheimer's disease. Can J Neurol Sci 16:516-527.
85. McGeer PL, Akiyama H, Itagaki S, McGeer EG. 1989b. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107:341-346.
86. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425-432.
87. Meda L, Bernasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos LJ, Mantovani A, Rossi F, Cassatella MA. 1996a. Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol 157:1213-1218.
88. Meda L, Bonaiuto C, Baron P, Otvos LJ, Rossi F, Cassatella MA. 1996b. Priming of monocyte respiratory burst by beta-amyloid fragment (25-35). Neurosci Lett 219:91-94.
89. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. 1999. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J Neuroimmunol 93:45-52.
90. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. 1990. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 145:2974-2983.
91. Molina H, Kinoshita T, Webster CB, Holers VM. 1994. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol 153:789-795.
92. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
93. Nakai M, Hojo K, Taniguchi T, Terashima A, Kawamata T, Hashimoto T, Maeda K, Tanaka C. 1998. PKC and tyrosine kinase involvement in amyloid beta (25-35)-induced chemotaxis of microglia. Neuroreport 9:3467-3470.
94. Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P Sr, Alafuzoff I. 1999. Reactive microglia in aging and dementia: An immunohistochemical study of postmortem human brain tissue. Acta Neuropathol (Berl) 97:383-392.
95. Pasinetti GM, Johnson SA, Rozovsky I, Lampert-Etchells M, Morgan DG, Gordon MN, Morgan TE, Willoughby D, Finch CE. 1992. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol 118:117-125.
96. Perlmutter LS, Scott SA, Barron E, Chui HC. 1992. MHC class II-positive microglia in human brain: Association with Alzheimer lesions. J Neurosci Res 33:549-558.
97. Perry VH, Hume DA, Gordon S. 1985. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience 15:313-326.
98. Petersen I, Baatrup G, Jepsen HH, Svehag SE. 1985. Complement-mediated solubilization of immune complexes and their interaction with complement C3 receptors. Complement 2:97-110.
99. Rogers J, Lue LF. 2001. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 39:333-340.
100. Rogers J, Luber-Narod J, Styren SD, Civin WH. 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9:339-349.
101. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P. 1992a. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89:10016-10020.
102. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I. 1992b. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89:10016-10020.
103. Rogers J, Lue L-F, Walker DG, Yan SD, Stern D, Strohmeyer R, Kovelowski CJ. 2002. Elucidating Molecular Mechanisms of Alzheimer's Disease in Culture Models, in Neuroinflammation - From Bench to Bedside. Heidelberg: Springer. p 25-44.
104. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. 1989. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101: 288-292.
105. Rozemuller JM, Stam FC, Eikelenboom P. 1990. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 119:75-78.
106. Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. 1997. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berl) 94:316-322.
107. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
108. Schenk DB, Seubert P, Lieberburg I, Wallace J. 2000. beta-peptide immunization: A possible new treatment for Alzheimer disease. Arch Neurol 57:934-936.
109. Schifferli JA,Taylor RP. 1989. Physiological and pathological aspects of circulating immune complexes. Kidney Int 35:993-1003.
110. Shen Y, Li R, McGeer EG, McGeer PL. 1997. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769:391-395.
111. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. 2000. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499.
112. Shigematsu K, McGeer PL, Walker DG, Ishii T, McGeer EG. 1992. Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage. J Neurosci Res 31:443-453.
113. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. 2001. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
114. Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. 1999. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 79:1247-1259.
115. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. 1999. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154:1673-1684.
116. Stalder M, Deller T, Staufenbiel M, Jucker M. 2001. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: No evidence of intracellular amyloid Neurobiol Aging 22:427-434.
117. Strohmeyer R, Shen Y, Rogers J. 2000. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 81:7-18.
118. Styren SD, Civin WH, Rogers J. 1990. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 110:93-104.
119. Taylor RP, Kujala G, Wilson K, Wright E, Harbin A. 1985. In vivo and in vitro studies of the binding of antibody/dsDNA immune complexes to rabbit and guinea pig platelets. J Immunol 134:2550-2558.
120. Terai K, Matsuo A, McGeer PL. 1996. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 735:159-168.
121. Terry RD, Wisniewski HM. 1975. Pathology and pathogenesis of dementia. In: Fields WS, editor. Neurological and Sensory Disorders in the Elderly. New York: Stratton. p 135-150.
122. Tomozawa Y, Inoue T, Takahashi M, Adachi M, Satoh M. 1996. Apoptosis of cultured microglia by the deprivation of macrophage colony-stimulating factor. Neurosci Res 25:7-15.
123. Walker DG, Kim SU, McGeer PL. 1995a. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 40:478-493.
124. Walker DG, Kim SU, McGeer PL. 1995b. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 40:478-493.
125. Walker DG, Lue LF, Beach TG. 2001. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 22:957-966.
126. Walker DG and McGeer PL. 1992. Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res 14:109-116.
127. Waxman FJ, Hebert LA, Cornacoff JB, VanAman ME, Smead WL, Kraut EH, Birmingham DJ, Taguiam JM. 1984. Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest 74:1329-1340.
128. Waxman FJ, Hebert LA, Cosio FG, Smead WL, VanAman ME, Taguiam JM, Birmingham DJ. 1986. Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest 77:82-89.
129. Webster S, Glabe C, Rogers J. 1995. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun 217:869-875.
130. Webster S, Bonnell B, Rogers J. 1997a. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am J Pathol 150:1531-1536.
131. Webster S, Bradt B, Rogers J, Cooper N. 1997b. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem 69:388-398.
132. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J. 1997c. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18:415-421.
133. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. 2000. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol 161:127-138.
134. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216.
135. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW. 1998. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18:2161-2173.
136. Yamada T, Yoshiyama Y, Kawaguchi N. 1997. Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Res 749:329-334.
137. Yamamoto-Sasaki M, Ozawa H, Saito T, Rosler M, Riederer P. 1999. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824:300-303.
138. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM. 1997. Amyloidbeta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 94:5296-5301.
139. Yao J, Harvath L, Gilbert DL, Colton CA. 1990. Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 27:36-42.
140. Yates SL, Burgess LH, Kocsis-Angle J, Antal JM, Dority MD, Embury PB, Piotrkowski AM, Brunden KR. 2000. Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 74:1017-1025.
141. Younkin SG. 1998. The role of A beta 42 in Alzheimer's disease. J Physiol (Paris) 92:289-292.
142. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, Frangione B, Ghiso J. 1994. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 205:1431-1437.
143. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. 1996. Glycoprotein 330/megalin: Probable role in recepter-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93:4229-4234.